The pharmacokinetics of anidulafungin during continuous venovenous hemofiltratio
Active, not recruiting
- Conditions
- intensive care patients with suspected or proven fungal infection, who undergo hemofiltrationMedDRA version: 9.1Level: LLTClassification code 10042941Term: Systemic fungal infection NOS
- Registration Number
- EUCTR2008-007753-12-AT
- Lead Sponsor
- MUW, Universitätsklinik für Innere Medizin I, Abteilung für Infektionskrankheiten und Tropenmedizin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
a)Age 19 to 70 years
b)Suspected or proven infection requiring parenteral antifungal therapy.
c)Continuous venovenous hemofiltration because of an acute renal failure.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
a)Known history of hypersensitivity to echinocandins.
b)An expected survival of less than three days.
c)Known alcohol dependency, epilepsy, pregnancy or liver failure.
d)Neutropenic patients
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: The study is conducted to investigate the pharmacokinetics of anidulafungin during CVVHDF in critically ill patients.;Secondary Objective: ;Primary end point(s): Pharmacokinetic Data in patients with renal insufficiency and hemofiltration
- Secondary Outcome Measures
Name Time Method